|

iGlarLixi (insulin glargine/lixisenatide) Clinical Trials

2 actively recruiting trials

▲ +1 trial since June 2026

Also known as: SOLIQUA®

Pipeline

Phase 4: 2

Top Sponsors

  • Shanghai Zhongshan Hospital1
  • Sanofi1

Indications

  • Diabetes2
  • Type 2 Diabetes (T2D)1
  • Type 2 Diabetes1

Other2 trials

Efficacy and Safety of iGlarLixi Versus Standard of Care in a Real-world Adult China Population With Uncontrolled Type 2 Diabetes on Oral Agents
Phase 4
iGlarLixi CGM Study in Chinese T2D Individuals After OADs
Phase 4

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.